Skip to main content
  • Solutions
  • for Consumers
  • Stories
  • About us

  • Newsroom
  • Careers
  • Contact us
NewsroomCareersContact us

Invalid URL

Invalid URL

Invalid URL

Tuesday, March 14, 2023
Stories / Publications /

Analytical and clinical validity of wearable, multi-sensor technology for assessment of motor function in patients with Parkinson's disease in Japan

Read more

Publication

Scientific reports

Author

Oyama G., Burq M., Hatano T., Marks W. J. Jr., Kapur R., Fernandez J., Fujikawa K., Furusawa Y., Nakatome K., Rainaldi E., Chen C., Ho K. C., Ogawa T., Kamo H., Oji Y., Takeshige-Amano H., Taniguchi D., Nakamura R., Sasaki F., Ueno S., Hattori N

Published

Tuesday, March 14, 2023

Share

Invalid URL

Invalid URL

Invalid URL

ABSTRACT

Continuous, objective monitoring of motor signs and symptoms may help improve tracking of disease progression and treatment response in Parkinson’s disease (PD). This study assessed the analytical and clinical validity of multi-sensor smartwatch measurements in hospitalized and home-based settings (96 patients with PD; mean wear time 19 h/day) using a twice-daily virtual motor examination (VME) at times representing medication OFF/ON states. Digital measurement performance was better during inpatient clinical assessments for composite V-scores than single-sensor–derived features for bradykinesia (Spearman |r|= 0.63, reliability = 0.72), tremor (|r|= 0.41, reliability = 0.65), and overall motor features (|r|= 0.70, reliability = 0.67). Composite levodopa effect sizes during hospitalization were 0.51–1.44 for clinical assessments and 0.56–1.37 for VMEs. Reliability of digital measurements during home-based VMEs was 0.62–0.80 for scores derived from weekly averages and 0.24–0.66 for daily measurements. These results show that unsupervised digital measurements of motor features with wrist-worn sensors are sensitive to medication state and are reliable in naturalistic settings.

Parkinson's Disease
Neurology
Digital Biomarkers

protected by reCAPTCHA